07:13 AM EST, 02/28/2025 (MT Newswires) -- Akero Therapeutics ( AKRO ) reported a Q4 loss Friday of $0.99, unchanged from a year earlier.

Two analysts polled by FactSet expected a loss of $1.19.

The company did not report any revenue for the quarter ended Dec. 31.

As of year-end, Akero had $797.8 million in cash, cash equivalents, and marketable securities that it expects to be sufficient for funding its current operating plan into 2028.